GlassScriptPhysician profile
Michael B Natter
NPI 1558896035
$33,976.85
in general payments reported to CMS, 2019-2025
9 companies · $31K in 2025
The $31K reported for 2025 was more than what 94% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $149 · 2023: $701 · 2024: $2,339 · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Travel and Lodging: $12K · Consulting Fee: $2,217 · Food and Beverage: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,624.00 |
| Travel and Lodging | $12,086.89 |
| Consulting Fee | $2,217.00 |
| Food and Beverage | $899.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $32,927.89 | 2024-2025 | |
| Beta Bionics, INC. | $330.48 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Cequr Corporation | $277.50 | 2022-2023 | Cequr Simplicity |
| Novo Nordisk INC | $185.36 | 2022-2025 | Ozempic, Rybelsus |
| Tandem Diabetes Care, INC. | $138.56 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Antares Pharma, INC. | $44.47 | 2024 | Xyosted |
| Lilly USA, LLC | $27.47 | 2023 | Jardiance |
| Insulet Corporation | $26.80 | 2024 | Omnipod |
| Halozyme INC | $18.32 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Natter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.